---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036749"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:00:08.375929+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ardelyx enters commercial supply agreement with Catalent for IBSRELA through 2028

## Summary
- Agreement covers tableting, testing, release and bulk packaging of IBSRELA (tenapanor HCl) at Catalent's Winchester, KY facility.
- Initial term through Dec 31, 2028, with automatic renewal for two-year terms thereafter.
- Minimum purchase commitment: minimum number of batches per contract year.
- Unit pricing adjusted annually starting Jan 1, 2025, based on producer price index.
- Either party can terminate for material breach after cure period.

## SEC filing metadata
- accession: 0001628280-24-036749
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828024036749/0001628280-24-036749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828024036749/ardx-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036749
- JSON: https://secwatch.observer/filing/0001628280-24-036749.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.